ICON Reports Second Quarter 2016 Results

ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has reported its financial results for the second quarter ended June 30, 2016.

Gross business wins in the second quarter were a record $622 million and cancellations in the quarter were $120 million, resulting in record net business wins of $502 million, a net book to bill of 1.22.

In the second quarter net revenue grew 5.7% year on year to $410.6 million from $388.7 million in the same quarter last year.

Income from operations, before non-recurring charges in the quarter, increased by 14.5% to $78.0 million or 19.0% of revenue, compared to $68.1 million or 17.5% for the same quarter last year.

Net income before non-recurring charges in the quarter increased by 10.4% to $64.7 million or $1.14 per share on a diluted basis, compared with $58.6 million or $0.95 per share for the same quarter last year.

Revenue in the first half of 2016 increased by 4.4% to $811.2 million from $776.9 million in 2015.

Income from operations in the first half of 2016, before non-recurring charges, increased by 14.3% to $154.0 million or 19.0% of revenue compared with $134.8 million or 17.4% of revenue in the previous year.

Net income in the first half of 2016, before non-recurring charges, increased by 11.5% to $127.6 million compared with $114.5 million last year. Year to date earnings increased by 22% to $2.26 per share on a diluted basis compared to $1.85 per diluted share last year.

Guidance for the full year 2016 has been updated with earnings reaffirmed in the range of $4.60 - $4.80 and revenue revised to a range of $1,665 - $1,680 million.

Day’s sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 46 days at June 30, 2016, compared with 47 days at the end of March 31, 2016 and 45 days at the end of June 2015.

Cash generated from operating activities for the quarter was $17.9 million. Capital expenditure for the quarter was $12.2 million. As a result, at June 30, 2016, the company had net debt of $97 million, compared to net debt of $100 million at March 31, 2016 and net cash of $132 million at end of June 2015.

At the company’s recent AGM we received shareholder approval to repurchase shares. We will implement a share repurchase programme of up to c$400m to be completed over the next 18-24 months.

During the quarter the company recorded a charge of $4.1 million in relation to restructuring costs. US GAAP income from operations after these items amounted to $73.9 million or 18% of revenue. US GAAP net income for the quarter was $61.0 million or $1.08 per diluted share.

CEO Ciaran Murray commented “Through a consistent focus on our strategic plan we achieved a record level of net business awards of $502 million and grew our backlog by almost 9% over last year. We delivered record revenue of $411 million and grew earnings per share by 20% to $1.14. We are reaffirming our 2016 earnings guidance to be in the range of $4.60 to $4.80 and revising our revenue guidance to be in the range of $1,665 - $1,680 million.”

  • <<
  • >>

Join the Discussion